Journal: Translational Lung Cancer Research
Article Title: Clinical and prognostic significance of detecting CEA , EGFR , LunX , c-met and EpCAM mRNA-positive cells in the peripheral blood, tumor-draining blood and bone marrow of non-small cell lung cancer patients
doi: 10.21037/tlcr-22-801
Figure Lengend Snippet: The percentage of specific genetic changes in tumor tissue. EGFR , epidermal growth factor receptor; c-met , met protooncogene; FGFR1, fibroblast growth factor receptor 1; c-myc , myc protooncogene; ALK , anaplastic lymphoma kinase; ROS1 , ros protooncogene 1; K-ras , Kirsten rat sarcoma viral oncogene homolog; BRAF , murine sarcoma viral oncogene homolog B; AC, adenocarcinoma; NAC, non-adenocarcinoma.
Article Snippet: We used break-apart probes for ALK (anaplastic lymphoma kinase) (Cytocell Ltd., Cambridge, United Kingdom) and ROS1 (ros protooncogene 1) (IntellMed, Olomouc, Czech Republic) gene rearrangements, along with LSI c-myc (myc protooncogen)/CEP8, LSI FGFR1 (fibroblast growth factor receptor 1)/CEP8, LSI EGFR /CEP7 and LSI c-met (met protooncogen)/CEP7 (all provided by IntellMed, Olomouc, Czech Republic) probes for gene/chromosome copy number enumeration.
Techniques: